Targeting adenosine A2A receptors in Parkinson's disease.
about
Dopamine dysregulation in a mouse model of paroxysmal nonkinesigenic dyskinesiaIntegrated signaling in heterodimers and receptor mosaics of different types of GPCRs of the forebrain: relevance for schizophreniaAdenosine signaling and function in glial cellsNucleus accumbens adenosine A2A receptors regulate exertion of effort by acting on the ventral striatopallidal pathwayA2A receptors in inflammation and injury: lessons learned from transgenic animalsThe 2.6 angstrom crystal structure of a human A2A adenosine receptor bound to an antagonistPotential therapeutic interest of adenosine A2A receptors in psychiatric disorders.Neural control of the lower urinary tractTherapy for Parkinson's disease: what is in the pipeline?Mechanisms of chemotherapy-induced behavioral toxicitiesStriatal pre- and postsynaptic profile of adenosine A(2A) receptor antagonistsNeurochemical measurement of adenosine in discrete brain regions of five strains of inbred miceUnprecedented therapeutic potential with a combination of A2A/NR2B receptor antagonists as observed in the 6-OHDA lesioned rat model of Parkinson's diseaseA2A adenosine receptor antagonism enhances synaptic and motor effects of cocaine via CB1 cannabinoid receptor activationAdenosine receptors as drug targets--what are the challenges?Mutation in ADORA1 identified as likely cause of early-onset parkinsonism and cognitive dysfunction.G protein-coupled receptor heterocomplexes in neuropsychiatric disorders.Novel Therapeutic GPCRs for Psychiatric Disorders.Adenosine A2A receptor signaling and golf assembly show a specific requirement for the gamma7 subtype in the striatumAdenosine receptor A2A deficiency in leukocytes increases arterial neointima formation in apolipoprotein E-deficient miceInactivation of the adenosine A2A receptor protects apolipoprotein E-deficient mice from atherosclerosisIdentification of zebrafish A2 adenosine receptors and expression in developing embryosSuppression of inflammatory and immune responses by the A(2A) adenosine receptor: an introduction.Adenosine A(2A) Receptor Antagonists Do Not Disrupt Rodent Prepulse Inhibition: An Improved Side Effect Profile in the Treatment of Parkinson's DiseaseAdenosine A(2A) receptors in psychopharmacology: modulators of behavior, mood and cognition.Adenosine A(2A) receptor mediates microglial process retractionDichotomous dopaminergic control of striatal synaptic plasticity.Systemic inflammation regulates microglial responses to tissue damage in vivoCocaine exposure modulates dopamine and adenosine signaling in the fetal brain.Inactivation of neuronal forebrain A receptors protects dopaminergic neurons in a mouse model of Parkinson's disease.Adenosine A2A receptor antagonism reverses inflammation-induced impairment of microglial process extension in a model of Parkinson's diseaseUsing caffeine and other adenosine receptor antagonists and agonists as therapeutic tools against neurodegenerative diseases: a review.Adenosine signaling during acute and chronic disease statesDecaffeinated coffee and nicotine-free tobacco provide neuroprotection in Drosophila models of Parkinson's disease through an NRF2-dependent mechanism.Xanthines as adenosine receptor antagonists.Synthesis and evaluation of 1,2,4-triazolo[1,5-c]pyrimidine derivatives as A2A receptor-selective antagonistsAstrocytes and therapeutics for Parkinson's disease.Theoretical considerations on the topological organization of receptor mosaicsPharmacophore mapping and in silico screening to identify new potent leads for A(2A) adenosine receptor as antagonists.Protective effect of metabotropic glutamate mGluR5 receptor elimination in a 6-hydroxydopamine model of Parkinson's disease.
P2860
Q24300992-1C1FFE74-9876-4287-9FE5-C683BB52060AQ24632803-BD8FC0FE-1095-47A0-B7F5-A1129FE56295Q24634273-37D0D752-B02A-44E8-B71E-D821A768D3EAQ24646576-4D3ED15F-E69F-4592-906E-B4B6A01DBE75Q24652486-D7C3D8E3-39BD-4F22-B6D1-00B48D82BBEFQ24654563-3AB61778-A388-42BF-B17A-F13623C6BF7EQ24657796-11591476-1F4B-4BFB-93C7-244D31C496A8Q26828785-B3074464-C891-4053-B6D3-7956294767A8Q26991826-A862BA2D-DC76-4B48-AFB4-A12A43E643D8Q26998870-968E3350-C6B8-4CF6-9312-44E118DB3976Q28476722-6C993E7E-F511-4A06-AD53-3D72E5B693AAQ28541087-5487E03A-DB3F-4BEC-BBE6-CD4F0F1E384AQ28542729-4571AD1F-0A14-4CA5-B3E8-CFF54F46E7C0Q28728678-C27686CC-FEA0-4A0F-902F-787AA18CB55EQ29346491-2D2142B0-5633-4285-9B8E-52B8D3C8BA5AQ29347530-B0AFE4BB-D963-4EB0-817A-7EB803124CAEQ30385233-E271ABE3-162E-4E2D-BAD5-2DB141F88470Q30407406-12A28B71-2D77-457C-B79E-8BFD792CAA27Q30430643-6364807F-7745-4541-9EED-AF41EEFEA798Q30432457-BE3F3151-97FD-4EA7-B453-B8FAABCE5948Q30435620-CDC04E63-C9DE-469B-A968-9030D96097CAQ30436906-8796410E-69A6-4CAB-9BDB-FF929D0E81F5Q30440124-CD9D0178-9385-4104-AD39-FEF6D298342EQ30472044-A2617C99-2F7F-4DDA-A9EE-B82D2D1B5FC2Q30482913-E8EA7121-61A6-4A7B-9008-A5ED96F47DFFQ30488894-9800F4A6-AF5C-4334-8273-106ED352B097Q30493521-A68DD7C0-F5DC-4953-B69B-B03F597080CAQ30643015-5F359989-2B95-4B48-BAA2-3217FB3A916EQ33618429-6E34B5B9-33B4-4CCE-934E-30FE94B8A7EAQ33645872-C35A3612-41F1-4876-8C9E-C822E89E6364Q33811654-E113A8F2-151B-449A-A48E-D05E3A93071FQ33971113-6B0201E7-96E6-41E7-BB6C-1A54EBF3CC55Q34035228-D4A51615-6CCD-4B72-A024-E5D068A564C3Q34111402-302230B9-8804-497B-BE2B-5A26F30245D6Q34139398-96EEB292-2E70-4B93-A884-403DB7DA6345Q34157260-B93D5520-3168-41C0-958C-6EFA14A88979Q34168266-10BD5565-14DC-46C7-9858-A53D313B9E17Q34171499-39B44F04-755F-4ABC-B80A-416D622B08A6Q34183010-46AC945E-DF75-4F21-A3FD-DA2787F4F198Q34269340-156E0C7D-483B-4AF3-8D95-E16D9CB3AF55
P2860
Targeting adenosine A2A receptors in Parkinson's disease.
description
2006 nî lūn-bûn
@nan
2006 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Targeting adenosine A2A receptors in Parkinson's disease.
@ast
Targeting adenosine A2A receptors in Parkinson's disease.
@en
Targeting adenosine A2A receptors in Parkinson's disease.
@nl
type
label
Targeting adenosine A2A receptors in Parkinson's disease.
@ast
Targeting adenosine A2A receptors in Parkinson's disease.
@en
Targeting adenosine A2A receptors in Parkinson's disease.
@nl
prefLabel
Targeting adenosine A2A receptors in Parkinson's disease.
@ast
Targeting adenosine A2A receptors in Parkinson's disease.
@en
Targeting adenosine A2A receptors in Parkinson's disease.
@nl
P2093
P1476
Targeting adenosine A2A receptors in Parkinson's disease.
@en
P2093
Jiang-Fan Chen
Luigi Agnati
Micaela Morelli
P304
P356
10.1016/J.TINS.2006.09.004
P577
2006-10-09T00:00:00Z